Accro Bioscience focuses on developing innovative biotechnological solutions aimed at advancing healthcare. The company specializes in the creation of cutting-edge therapeutic products that leverage advanced biological processes. Their pipeline includes a range of products designed to address unmet medical needs, utilizing proprietary technologies that enhance the efficacy and safety of treatments. Accro Bioscience emphasizes a commitment to research and development, ensuring that their offerings are at the forefront of scientific advancements.

The technologies employed by Accro Bioscience encompass a variety of methodologies, including but not limited to, novel drug delivery systems and biologics that target specific disease mechanisms. Their approach integrates insights from molecular biology and biochemistry to optimize therapeutic outcomes. By focusing on precision medicine, Accro Bioscience aims to tailor treatments to individual patient profiles, thereby improving overall treatment effectiveness and minimizing side effects. This strategic focus on innovative technologies positions the company as a leader in the biotechnology sector.

China

Accro Bioscience (Suzhou) Limited is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. The company is a leading biotechnology company based in China and is privately-held. Accro Bioscience is dedicated to the development of treatments for inflammatory conditions and has recently announced a Series B funding round of over $50 million.

Accro Bioscience

Company Details